ACC.24: Late-Breaking Science Video Collection

Published: 06 April 2024

  • Views:

    Views Icon 4961
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Our recurring review series, View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offers a thorough examination of late-breaking and featured scientific findings, highlighting significant data.

 

To delve deeper into the pivotal clinical trial data unveiled at ACC 24, Dr Harriette Van Spall (McMaster University, Hamilton, CA) conducts interviews with the principal investigators as part of her Late-Breaker Discussion Series.

 

For brief and focused coverage of the essential data unveiled, our accessible Expert Interviews were conducted with a select group of faculty members, concentrating on the results, relevance, and implications for future research.

 

Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.

More from this programme

Part 1

View from the Thoraxcenter

In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC.24. 

Part 2

Late-Breaker Discussion Series

Part 5

Behind the Heart

Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.

About the episode

ACC.24 — We are joined onsite by Dr David Austin (South Tees Hospitals NHS Foundation Trust, UK) to discuss the findings from the PROACT trial (NCT03265574).

Anthracyclines used in the treatment of breast cancer cause damage to the muscle cells in the heart, resulting in cardiotoxicity

PROACT is a phase III randomised superiority trial of enalapril for the prevention of anthracycline-induced cardiotoxicity in patients treated for breast cancer and lymphoma. Patients due to receive anthracycline chemotherapy (epirubicin dose >300mg/m2) at four different centers in the UK were invited to participate in the study, resulting in an enrollment of 170 participants. Recieved chemotherapy dose was 328mg/m2 doxorubicin-equivalent. 

Findings showed that enalapril did not affect myocardial injury or cardiac function outcomes. 81% of patients had myocardial injury on cardiac troponin T criteria, and 46% of patients had myocardial injury on cardiac troponin I criteria. 21% had a >15% relative decrease in left ventricular global longitudinal strain, and 2% had a >10% reduction in left ventricular ejection fraction to <50%.

Interview Questions: 

  1. What is the importance of this study?
  2. What was the study design and patient population?
  3. What are the key findings revealed at ACC?
  4. What are the implications of these findings on clinical practice?
  5. What are the knowledge gaps?
  6. What are the next steps?

Recorded onsite at the ACC Conference in Atlanta, 2024.

Faculty Biographies

David Austin

View full profile

Comments

You must be to comment. If you are not registered, you can register here.